Second Genome
PrivateLast Round
M&A
Jan 2, 2024
Total Funding Raised
$114.36M
Company Overview
Second Genome is a biotechnology company that utilizes a microbiome data platform to extract microbial genetic insights for the development of precision therapies and biomarkers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Healthcare Analytics, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Second Genome Comparables
Compare Second Genome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Microbiotica | 78% | |
| Nuanced Health | 78% | |
| Cmbio | 76% |
Second Genome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jan 2, 2024 | ||||
| Corporate Funding | Apr 6, 2020 | ||||
| Grant | Sep 1, 2019 | ||||
| Grant | Jul 1, 2017 | ||||
| Series B Extension | Jul 13, 2016 | ||||
Series B | Apr 20, 2016 |
Second Genome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series B |
| Digitalis Ventures | Series B, Series B Extension |
| Schroder Adveq | Series B |
| NIH RADx | Grant |
| Wavepoint Ventures | Seed, Series A |
| Lifeforce Capital | Series B |
| Seraph Group | Series B, Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 2, 2024
Completed an M&A funding round.
- Sep 1, 2019
$967K grant received from NIH RADx.
Second Genome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Second Genome's valuation, stock price, and market status.
Is Second Genome a public or private company?
Second Genome is a private company.
What is the current stock price of Second Genome?
Second Genome is a private company with no public stock price. No recent secondary market data is available.
How much is Second Genome worth (valuation)?
Valuation information for Second Genome is not publicly available.
Can I buy Second Genome stock?
Second Genome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Second Genome's last funding round?
Second Genome's most recent funding round was Corporate Funding on April 6, 2020.
Who are the main investors in Second Genome?
Key investors in Second Genome include NIH RADx, Wavepoint Ventures, Roche Venture Fund, Advanced Technology Ventures, Pfizer Ventures.
Will Second Genome IPO soon?
No public IPO plans have been announced for Second Genome.
How can I track Second Genome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Second Genome's secondary market activity and sign up for updates.